Floatz logo

Daunomycin

Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
89/ 100

Competitive context

15 Active assets in the Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation cohort.

Asset / SponsorPhaseRating
Etoposide
Alice Mims
Phase 3BBB
Cytarabine
The First Affiliated Hospital of Soochow University
Phase 3BBB
Idarubicin
The First Affiliated Hospital of Soochow University
Phase 2BBB
Mitoxantrone
BGI, China
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Daunomycin is also rated in:

acute myeloid leukemia by FAB classificationActive
BBB
Indicative · Phase 3
78 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesActive
BBB
Indicative · Phase 3
77 / 100
View asset →
acute monocytic leukemiaActive
BBB
Indicative · Phase 3
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →